Clinical Rubik's Cube: Global Clinical Trials in Hungary
Green Chemistry Principles
The Price Of Innovation New Drug Development Cost 2003
SPCs as Targets for Litigation: C5 Presentation 18 February 2009
© IFPMA 2009 IFPMA to WHO EWG 12 Jan 09 1 Alicia D. Greenidge, Director General, IFPMA WHO Expert Working Group, Geneva, 12 Jan 2009 IFPMA Presentation.
Infrastructures For Information Inc. The Collaborative XML Content Company Content Company.
Challenges for the Research-Based Industry Review of New Drug Development Kenneth I Kaitin, Ph.D. Director, Tufts Center for the Study of Drug Development.
Praveen Balimane Addresses SLAS ADMET Special Interest Group at SLAS2015
Optimizing Protocol Planning, Feasibility, and Site Selection through an Integrated View of Clinical Trial Operations and Other Data Sources
What Do Doctors Think About Biosimilars?
Overcoming challenges in Drug Development
Robert R. Ruffolo, Jr., Ph.D., D.Sc.(h), D.Eng.(h) President, Research & Development Wyeth Pharmaceuticals Senior Vice President Wyeth (Corporation) Directors.
